| Document and Entity Information - shares | 3 Months Ended | |
| Mar. 31, 2018 | May 14, 2018 | |
| Document and Entity Information | ||
| Entity Registrant Name | REFLECT SCIENTIFIC INC | |
| Document Type | 10-Q | |
| Document Period End Date | Mar. 31, 2018 | |
| Amendment Flag | false | |
| Entity Central Index Key | 1,103,090 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Common Stock, Shares Outstanding | 71,312,086 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Current Reporting Status | Yes | |
| Entity Voluntary Filers | No | |
| Entity Well-known Seasoned Issuer | No | |
| Document Fiscal Year Focus | 2,018 | |
| Document Fiscal Period Focus | Q1 | |
| Trading Symbol | rscf |
| REFLECT SCIENTIFIC, INC. Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2018 | Dec. 31, 2017 |
| CURRENT ASSETS | ||
| Cash | $ 242,676 | $ 235,858 |
| Accounts receivable, net | 151,922 | 122,435 |
| Inventory, net | 149,217 | 155,352 |
| Prepaid assets | 3,100 | 3,100 |
| Total Current Assets | 546,915 | 516,745 |
| OTHER ASSETS | ||
| Goodwill | 60,000 | 60,000 |
| Deposits | 3,100 | 3,100 |
| Total Other Assets | 63,100 | 63,100 |
| TOTAL ASSETS | 610,015 | 579,845 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expense | 54,808 | 53,507 |
| Customer deposits | 960 | 70,812 |
| Income taxes payable | 100 | 100 |
| Total Current Liabilities | 55,868 | 124,419 |
| Total Liabilities | 55,868 | 124,419 |
| COMMITMENTS AND CONTINGENCIES | ||
| STOCKHOLDERS' EQUITY | ||
| Preferred stock, $0.01 par value, authorized 5,000,000 shares; No shares issued and outstanding | 0 | 0 |
| Common stock, $0.01 par value, authorized 100,000,000 shares; 71,312,086 and 71,312,086 issued and outstanding, respectively | 713,120 | 713,120 |
| Additional paid in capital | 19,793,490 | 19,793,490 |
| Accumulated deficit | (19,952,463) | (20,051,184) |
| Total Stockholders' Equity | 554,147 | 455,426 |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 610,015 | $ 579,845 |
| Reflect Scientific, Inc. Balance Sheet (Parenthetical) - $ / shares | Mar. 31, 2018 | Dec. 31, 2017 |
| Statement of Financial Position | ||
| Preferred stock authorized | 5,000,000 | 5,000,000 |
| Preferred stock par value | $ 0.01 | $ 0.01 |
| Preferred stock outstanding | 0 | 0 |
| Preferred stock issued | 0 | 0 |
| Common stock authorized | 100,000,000 | 100,000,000 |
| Common stock par value | $ 0.01 | $ 0.01 |
| Common stock outstanding | 71,312,086 | 71,312,086 |
| Common stock issued | 71,312,086 | 71,312,086 |
| REFLECT SCIENTIFIC, INC. Condensed Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2018 | Mar. 31, 2017 | |
| Income Statement | ||
| REVENUES | $ 425,681 | $ 255,915 |
| COST OF GOODS SOLD | 109,310 | 90,028 |
| GROSS PROFIT | 316,371 | 165,887 |
| OPERATING EXPENSES | ||
| Salaries and wages | 112,761 | 105,280 |
| Rent expense | 8,983 | 8,578 |
| Research and development expense | 14,905 | 11,630 |
| General and administrative expense | 81,001 | 42,787 |
| Total Operating Expenses | 217,650 | 168,275 |
| OPERATING INCOME (LOSS) | 98,721 | (2,388) |
| OTHER EXPENSE | ||
| Total Other Expenses | 0 | 0 |
| NET INCOME (LOSS) BEFORE TAXES | 98,721 | (2,388) |
| Provision for income taxes | 0 | 0 |
| NET INCOME (LOSS) | $ 98,721 | $ (2,388) |
| NET INCOME (LOSS) PER SHARE - BASIC AND DILUTED | $ 0 | $ 0 |
| WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED | 71,312,086 | 65,401,086 |
| REFLECT SCIENTIFIC, INC. Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
| Mar. 31, 2018 | Mar. 31, 2017 | |
| CASH FLOWS FROM OPERATING ACTIVITIES | ||
| NET INCOME (LOSS) | $ 98,721 | $ (2,388) |
| Adjustments to reconcile net income to net cash used in operating activities: | ||
| Accounts receivable | (29,487) | 12,096 |
| Inventory | 6,135 | (5,491) |
| Accounts payable and accrued expenses | 1,301 | (34,722) |
| Customer deposits | (69,852) | 130 |
| Net Cash (used in) provided by Operating Activities | 6,818 | (30,375) |
| CASH FLOWS FROM INVESTING ACTIVITIES | ||
| Net Cash used in investing Activities | 0 | 0 |
| CASH FLOWS FROM FINANCING ACTIVITIES | ||
| Net Cash used in Financing Activities | 0 | 0 |
| NET CHANGE IN CASH | 6,818 | (30,375) |
| CASH AT BEGINNING OF PERIOD | 235,858 | 263,964 |
| CASH AT END OF PERIOD | 242,676 | 235,589 |
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||
| Interest | 0 | 0 |
| Income taxes | $ 0 | $ 0 |
| Organization, Consolidation and Presentation of Financial Statements | 3 Months Ended |
| Mar. 31, 2018 | |
| Notes | |
| Organization, Consolidation and Presentation of Financial Statements | NOTE 1 - The accompanying unaudited condensed consolidated financial statements have been prepared by the Company pursuant to accounting principles generally accepted in the United States of America. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission. The information furnished in the interim condensed consolidated financial statements includes normal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentation of such financial statements. Although management believes the disclosures and information presented are adequate to make the information not misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with the Companys most recent audited consolidated financial statements and notes thereto included in its December 31, 2017 financial statements. Operating results for the three months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. NOTE 2 - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND LINE OF BUSINESS: Cole, Inc. (the Company) was incorporated under the laws of the State of Utah on November 3, 1999. The Company was organized to engage in any lawful activity for which corporations may be organized under the Utah Revised Business Corporation Act. On December 30, 2003 the Company changed its name to Reflect Scientific, Inc. Reflect Scientific designs, develops and sells scientific equipment for the Life Science and Manufacturing industries. The Companys business activities include the manufacture and distribution of unique laboratory consumables and disposables such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, graphite and vespel/graphite sealing components for use by original equipment manufacturers (OEM) in the chemical analysis industries, primarily in the field of gas/liquid chromatography. The Companys chemical detector products serve the analytical instrumentation sector of the Life Sciences market. These optically based chemical detection instruments provide a cost-effective, high-performance alternative for original equipment manufacturers (OEM). One major use for these detectors is the analysis of whole blood for metabolic diseases. SIGNIFICANT ACCOUNTING POLICIES: PRINCIPLES OF CONSOLIDATION: USE OF ESTIMATES: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. REVENUE RECOGNITION: The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to exchange for those goods or services. The Company only applies the five step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1. Identify the contract with the customer Step 2. Identify the performance obligations in the contract Step 3. Determine the transaction price Step 4. Allocate the transaction price to the performance obligations in the contract Step 5. Recognize revenue when the Company satisfied a performance obligation ACCOUNTS RECEIVABLE: Accounts receivables are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customers historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection. At March 31, 2018 and December 31, 2017, the Company had accounts receivable, net of the allowance, of $151,922 and $122,435, respectively. At March 31, 2018 and December 31, 2017 the allowance for doubtful accounts was $4,000 and $4,000, respectively. INVENTORY: Inventories are presented net of an allowance for obsolescence and are stated at the lower of cost or market value based upon the average cost inventory method. The Companys inventory consists of parts for scientific vial kits, refrigerant gases, components for detectors and ultra-low temperature freezers which it builds and other scientific items. At March 31, 2018, inventory was made up of $235,558 of finished goods, less an allowance for obsolescence of $86,339. At December 31, 2017, inventory was comprised of $241,691 of finished goods, less an allowance for obsolescence of $86,339. There were no raw materials or work in progress for either period presented. INTANGIBLE ASSETS: Costs to obtain or develop patents are capitalized and amortized over the life of the patents. Patents are amortized from the date the Company acquires or is awarded the patent over their estimated useful lives, which range from 5 to 15 years. An impairment charge is recognized if the carrying amount is not recoverable and the carrying amount exceeds the fair value of the intangible assets as determined by projected discounted net future cash flows. We perform an impairment analysis on an annual basis. The Companys analysis did not indicate any impairment of intangible assets as of the impairment analysis conducted December 31, 2017. GOODWILL: Goodwill represents the excess of the Companys acquisition cost over the fair value of net assets of the acquisition. Goodwill is not amortized, but is tested for impairment annually, or when a triggering event occurs. As described in ACS 360, the Company has adopted the two step goodwill impairment analysis that includes quantitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. A fair-value-based test is applied at the overall Company level. The test compares the estimated fair value of the Company at the date of the analysis to the carrying value of its net assets. The analysis also requires various judgments and estimates, including general and macroeconomic conditions, industry and the Companys targeted market conditions, as well as relevant entity-specific events, such as a change in the market for the Companys products and services. After considering the qualitative factors that would indicate a need for interim impairment of goodwill and applying the two-step process described in ASC 360, management has determined that the value of Companys assets is not more likely than not less than the carrying value of the Company including goodwill, and that no impairment charge needs be recognized during the reporting periods. RESEARCH AND DEVELOPMENT EXPENSE - The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board's Accounting Standard Codification Topic 730 Research and Development". Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. EARNINGS PER SHARE: The computation of basic earnings per share of common stock is based on the weighted average number of shares outstanding during the period. Diluted EPS is computed by dividing net earnings by the weighted-average number of common shares and dilutive common stock equivalents during the period. Common stock equivalents are not used in calculating dilutive EPS when their inclusion would be anti-dilutive. At March 31, 2018 and 2017, the Company had no common stock equivalents. RECENT ACCOUNTING PRONOUNCEMENTS: Public law No. 115-97, known as the Tax Cuts and Jobs Act the Tax Act). Enacted on December 22, 2017, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. Also on December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (SAB 118), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period of up to one year from the enactment date to complete the accounting. Any adjustments during this measurement period will be included in net earnings from continuing operations as an adjustment to income tax expense in the reporting period when such adjustments are determined. As the Company has net operating loss carryforwards which will offset tax liability for the coming year or years, no adjustments for the effect of the income tax rate change is reflected in our financial statements. In January 2018 the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company is using the ASU 606 five step model, outlined in Note 2 to the financial statements. We have completed our assessment of the impact under the new revenue standard on our condensed financial statements. Based on our assessment, we have concluded that our financial statements will not be materially impacted upon adoption. In February 2018, the Financial Standards Accounting Board (FASB) issued Accounting Statement Update No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations. |
| Going Concern | 3 Months Ended |
| Mar. 31, 2018 | |
| Notes | |
| Going Concern | NOTE 3 - GOING CONCERN The Company continues to accumulate significant operating losses and has an accumulated deficit of $19,952,463 at March 31, 2018. These factors raise substantial doubt about the Companys ability to continue as a going concern for a period of one year from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of these uncertainties. Management has taken a number of actions to reduce expenses. Management is seeking additional funding through the capital markets to facilitate the settlement of the remaining debentures, as well as to provide operating capital for its operations. However, there is no assurance that additional funding will be available on acceptable terms, if at all. |
| Subsequent Events | 3 Months Ended |
| Mar. 31, 2018 | |
| Notes | |
| Subsequent Events | NOTE 4 SUBSEQUENT EVENTS In accordance with ASC 855-10 management reviewed all material events through the date of this report. There are no material subsequent events to report. |
| Significant Accounting Policies (Policies) | 3 Months Ended |
| Mar. 31, 2018 | |
| Policies | |
| Principles of Consolidation | PRINCIPLES OF CONSOLIDATION: |
| Use of Estimates | USE OF ESTIMATES: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. |
| Revenue Recognition Accounting | REVENUE RECOGNITION: The Company recognizes revenue under ASC 606, Revenue from Contracts with Customers. The core principle of the new revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled to exchange for those goods or services. The Company only applies the five step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1. Identify the contract with the customer Step 2. Identify the performance obligations in the contract Step 3. Determine the transaction price Step 4. Allocate the transaction price to the performance obligations in the contract Step 5. Recognize revenue when the Company satisfied a performance obligation |
| Accounts Receivable | ACCOUNTS RECEIVABLE: Accounts receivables are presented net of an allowance for doubtful accounts. The Company maintains allowances for doubtful accounts for estimated losses. The Company reviews the accounts receivable on a periodic basis and makes general and specific allowances when there is doubt as to the collectability of individual balances. In evaluating the collectability of individual receivable balances, the Company considers many factors, including the age of the balance, a customers historical payment history, its current credit-worthiness and current economic trends. Accounts are written off after exhaustive efforts at collection. At March 31, 2018 and December 31, 2017, the Company had accounts receivable, net of the allowance, of $151,922 and $122,435, respectively. At March 31, 2018 and December 31, 2017 the allowance for doubtful accounts was $4,000 and $4,000, respectively. |
| Inventory | INVENTORY: Inventories are presented net of an allowance for obsolescence and are stated at the lower of cost or market value based upon the average cost inventory method. The Companys inventory consists of parts for scientific vial kits, refrigerant gases, components for detectors and ultra-low temperature freezers which it builds and other scientific items. At March 31, 2018, inventory was made up of $235,558 of finished goods, less an allowance for obsolescence of $86,339. At December 31, 2017, inventory was comprised of $241,691 of finished goods, less an allowance for obsolescence of $86,339. There were no raw materials or work in progress for either period presented. |
| Intangible Assets | INTANGIBLE ASSETS: Costs to obtain or develop patents are capitalized and amortized over the life of the patents. Patents are amortized from the date the Company acquires or is awarded the patent over their estimated useful lives, which range from 5 to 15 years. An impairment charge is recognized if the carrying amount is not recoverable and the carrying amount exceeds the fair value of the intangible assets as determined by projected discounted net future cash flows. We perform an impairment analysis on an annual basis. The Companys analysis did not indicate any impairment of intangible assets as of the impairment analysis conducted December 31, 2017. |
| Goodwill | GOODWILL: Goodwill represents the excess of the Companys acquisition cost over the fair value of net assets of the acquisition. Goodwill is not amortized, but is tested for impairment annually, or when a triggering event occurs. As described in ACS 360, the Company has adopted the two step goodwill impairment analysis that includes quantitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. A fair-value-based test is applied at the overall Company level. The test compares the estimated fair value of the Company at the date of the analysis to the carrying value of its net assets. The analysis also requires various judgments and estimates, including general and macroeconomic conditions, industry and the Companys targeted market conditions, as well as relevant entity-specific events, such as a change in the market for the Companys products and services. After considering the qualitative factors that would indicate a need for interim impairment of goodwill and applying the two-step process described in ASC 360, management has determined that the value of Companys assets is not more likely than not less than the carrying value of the Company including goodwill, and that no impairment charge needs be recognized during the reporting periods. |
| Research and Development Expense | RESEARCH AND DEVELOPMENT EXPENSE - The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board's Accounting Standard Codification Topic 730 Research and Development". Under ASC 730, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. |
| Earnings Per Share | EARNINGS PER SHARE: The computation of basic earnings per share of common stock is based on the weighted average number of shares outstanding during the period. Diluted EPS is computed by dividing net earnings by the weighted-average number of common shares and dilutive common stock equivalents during the period. Common stock equivalents are not used in calculating dilutive EPS when their inclusion would be anti-dilutive. At March 31, 2018 and 2017, the Company had no common stock equivalents. |
| Recent Accounting Pronouncements | RECENT ACCOUNTING PRONOUNCEMENTS: Public law No. 115-97, known as the Tax Cuts and Jobs Act the Tax Act). Enacted on December 22, 2017, reduced the U.S. federal corporate tax rate from 35% to 21% effective January 1, 2018. Also on December 22, 2017, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (SAB 118), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period of up to one year from the enactment date to complete the accounting. Any adjustments during this measurement period will be included in net earnings from continuing operations as an adjustment to income tax expense in the reporting period when such adjustments are determined. As the Company has net operating loss carryforwards which will offset tax liability for the coming year or years, no adjustments for the effect of the income tax rate change is reflected in our financial statements. In January 2018 the Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The Company is using the ASU 606 five step model, outlined in Note 2 to the financial statements. We have completed our assessment of the impact under the new revenue standard on our condensed financial statements. Based on our assessment, we have concluded that our financial statements will not be materially impacted upon adoption. In February 2018, the Financial Standards Accounting Board (FASB) issued Accounting Statement Update No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The Company has reviewed all other recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its consolidated results of operation, financial position and cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its current or future earnings or operations. |
| Significant Accounting Policies (Details) - USD ($) | Mar. 31, 2018 | Dec. 31, 2017 |
| Details | ||
| Accounts Receivable, Gross | $ 151,922 | $ 122,435 |
| Allowance for bad debt | 4,000 | 4,000 |
| Inventory, Gross | 235,558 | 241,691 |
| Allowance for obsolescence | $ 86,339 | $ 86,339 |
| Going Concern (Details) - USD ($) | Mar. 31, 2018 | Dec. 31, 2017 |
| Details | ||
| Accumulated deficit | $ 19,952,463 | $ 20,051,184 |
